Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Department of Nuclear Medicine, University Hospital of Würzburg, Würzburg, Germany.
J Nucl Med. 2022 Jan;63(1):96-99. doi: 10.2967/jnumed.121.262206. Epub 2021 May 28.
C-X-C motif chemokine receptor 4 (CXCR4) is an attractive target for cancer diagnosis and treatment, as it is overexpressed in many solid and hematologic malignancies. This study investigated the feasibility of CXCR4-directed imaging with PET/CT using Ga-pentixafor to visualize and quantify disease involvement in myeloproliferative neoplasms (MPNs). Twelve patients with MPNs (4 with primary myelofibrosis, 6 with essential thrombocythemia, and 2 with polycythemia vera) and 5 controls underwent Ga-pentixafor PET/CT. Imaging findings were compared with immunohistochemical stainings, laboratory data, and splenic volume. Ga-pentixafor PET/CT was visually positive in 12 of 12 patients, and CXCR4 target specificity could be confirmed by immunohistochemical staining. A significantly higher tracer uptake could be detected in the bone marrow of MPN patients (SUV, 6.45 ± 2.34 vs. 4.44 ± 1.24). Dynamic changes in CXCR4 expression determined by Ga-pentixafor PET/CT corresponded with treatment response. Ga-pentixafor PET/CT represents a novel diagnostic tool to noninvasively detect and quantify the extent of disease involvement in MPNs.
C-X-C 基序趋化因子受体 4（CXCR4）是癌症诊断和治疗的一个有吸引力的靶点，因为它在许多实体瘤和血液恶性肿瘤中过表达。本研究探讨了使用 Ga-戊昔福（pentixafor）进行 PET/CT 引导的 CXCR4 靶向成像的可行性，以可视化和量化骨髓增殖性肿瘤（MPNs）中的疾病受累情况。12 名 MPN 患者（4 名原发性骨髓纤维化，6 名原发性血小板增多症，2 名真性红细胞增多症）和 5 名对照者接受了 Ga-戊昔福 PET/CT 检查。将影像学结果与免疫组织化学染色、实验室数据和脾脏体积进行比较。Ga-戊昔福 PET/CT 在 12 名患者中的 12 名中呈阳性，免疫组织化学染色可证实 CXCR4 靶特异性。MPN 患者的骨髓中可检测到明显更高的示踪剂摄取（SUV，6.45±2.34 比 4.44±1.24）。Ga-戊昔福 PET/CT 确定的 CXCR4 表达动态变化与治疗反应相对应。Ga-戊昔福 PET/CT 是一种新的诊断工具，可无创性检测和量化 MPN 中疾病受累的程度。
